Abstract: The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.

Abstract: The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.

Abstract: The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiratetone acetate in the stomach.

Abstract: The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu K? radiation, and the composition is free of surfactant, and the composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% Tween 20) at 37° C., 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% Tween 20) at 37° C., 75 rpm in a USP apparatus II. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinaemia (WM).

Abstract: The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu K? radiation, and the composition is free of surfactant, and the composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% Tween 20) at 37° C., 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% Tween 20) at 37° C., 75 rpm in a USP apparatus II. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinaemia (WM).